BPC-157 & TB-500: The Truth About the Wolverine Stack
A urologist reviews the evidence on BPC-157, TB-500 and their combination, covering origins, mechanisms, the human data gap, patent economics and grey-market risks.
With Dr. Alex Tatem (board-certified urologist, fellowship-trained men's health specialist)
Key moments
Tap a moment to play the video from there.
- 0:00Why it is called WolverineTatem introduces the stack, jokes about its internet reputation and says the name does not mean it delivers superhero results. He sets out the plan to test the claims against published literature.
- 2:42Where BPC-157 came fromHe describes BPC-157 as a synthetic 15 amino acid fragment of a gastric juice protein, developed by a Zagreb group. He notes that most of the research comes from that single group.
- 4:25Thymosin beta 4 and TB-500Tatem traces thymosin beta 4 back to thymus research in the 1960s and says TB-500 is a seven amino acid synthetic piece of its active region.
- 6:34Proposed mechanisms for BPC-157He lists nitric oxide, blood vessel growth, ERK1/2 and tendon cell pathways that studies have linked to BPC-157.
- 8:42How TB-500 is thought to workHe explains actin regulation and says a 2024 study suggested a breakdown product of TB-500 may drive its wound-healing activity in cell assays.
- 10:16Preclinical versus human evidenceTatem says preclinical BPC-157 data is extensive but human data is thin, with unpublished phase 2 results. He says TB-500 has no published human trials.
- 13:11The stack is only a theoryHe calls the rationale for combining the two reasonable but says no published study has tested the combination in any model.
- 14:01Patent law and drug developmentHe argues that US court rulings on naturally occurring molecules weaken patent incentives, which he says explains why large drug companies have not funded trials.
- 17:18Safety and grey-market qualityTatem covers the clean preclinical safety record, the open cancer-related question about blood vessel growth, and reported contamination and low purity in unregulated products.
- 24:53His conclusion and call for trialsHe sums up that the compounds are promising but unproven in people, and asks for independent, publicly funded multicenter trials.
What the video says
Dr. Alex Tatem, a urologist who runs a men's health center, goes through the published literature on BPC-157 and TB-500, the pair often called the "Wolverine stack." The tone is jokey, but the structure is a conventional evidence review. He starts with where each compound comes from. According to Tatem, BPC-157 is a 15 amino acid fragment of a protein found in gastric juice, developed by a research group in Zagreb. TB-500 is a seven amino acid piece of thymosin beta 4, a protein first characterized decades earlier.
Tatem then walks through the mechanisms he says have been proposed. For BPC-157 he lists nitric oxide signaling, new blood vessel growth, ERK1/2 signaling and a tendon cell pathway. For TB-500 he describes regulation of actin, a structural protein that governs cell movement. He also mentions a 2024 finding that a breakdown product of TB-500 may account for its wound-healing activity in cell assays.
The central argument is a gap between preclinical and human evidence. He calls the preclinical BPC-157 data extensive but says over 80% of it comes from one research group, and that human data is limited to small uncontrolled studies and unpublished phase 2 results. He states there are no published human trials of TB-500 and no studies of any kind on the combination. He cites better human data only for the full thymosin beta 4 protein, in dry eye and a heart attack trial.
He then explains why he thinks drug companies have not developed these peptides, pointing to US patent law on naturally occurring molecules. In the risk section he covers the clean preclinical safety record, the unanswered question about long-term effects of promoting blood vessel growth, reported contamination and impurity in grey-market products, and anti-doping and military restrictions.
His closing view is that the compounds are interesting but unproven in people. He calls for independent, publicly funded multicenter trials, and he leaves the decision to the viewer, with a short list of considerations for anyone thinking about using them.
On each compound
BPC-1572:42
Tatem describes BPC-157 as a synthetic 15 amino acid peptide from the Zagreb group, with extensive preclinical data and only small, uncontrolled human studies. He says its published safety record is clean but long-term human data is missing.
See how your DNA reads BPC-157TB-5004:25
Tatem describes TB-500 as a seven amino acid piece of thymosin beta 4 that acts through actin regulation. He says there are zero published human trials of TB-500 itself, though the full protein has some early clinical data.
See how your DNA reads TB-500“The Wolverine stack is an entirely theoretical construct.”
“promise and proof are two different things”
What this video doesn’t settle
- It does not establish whether BPC-157 works in people, since the human data it cites is small, uncontrolled or unpublished.
- It does not establish any human efficacy or safety for TB-500, which Tatem says has no published human trials.
- It does not establish whether combining the two helps, hurts or does nothing, since Tatem says no study has tested it.
Questions this video answers
Is there human evidence for BPC-157?
Tatem says it is thin. He cites unpublished phase 2 trials, a 2024 uncontrolled pilot study in 12 women with interstitial cystitis, and a knee injection case series without controls.
Has the BPC-157 and TB-500 combination been studied?
According to Tatem, no. He says zero published studies have evaluated the combination in any model system, so the Wolverine stack is a theoretical construct.
Why aren't BPC-157 and TB-500 FDA approved drugs?
Tatem argues that patent law makes it hard to protect naturally occurring molecules, so companies have little incentive to pay for large trials. He says public funding may be needed.
What risks does Tatem raise about grey-market peptides?
He cites independent testing that found heavy metals, bacterial endotoxins, wrong sequences and purity as low as 5 to 75%. He also notes that both compounds are prohibited by the World Anti-Doping Agency.
Does Tatem think BPC-157 and TB-500 are safe?
He says the preclinical safety record is clean but that this does not prove safety in people. He raises an unanswered question about long-term effects because both promote blood vessel growth.
Video by Dr. Alex Tatem on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
